	US 12,465,592 B2
	Structured encapsulated silicon-containing particles
Roghieh Suzanne Saffie-Siebert, Guildford (GB); and Flavia Maria Sutera, Guildford (GB)
Assigned to SISAF LIMITED, Guildford (GB)
Appl. No. 17/599,020
Filed by SISAF LIMITED, Guildford (GB)
PCT Filed Mar. 30, 2020, PCT No. PCT/GB2020/050853 § 371(c)(1), (2) Date Sep. 28, 2021, PCT Pub. No. WO2020/193998, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 19165904 (GB), filed on Mar. 28, 2019.
Prior Publication US 2022/0184038 A1, Jun. 16, 2022
Int. Cl. A61K 31/4174 (2006.01); A61K 9/06 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 31/343 (2006.01); A61K 31/4196 (2006.01); A61K 31/496 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61K 47/44 (2017.01); A61P 31/10 (2006.01); B01J 13/08 (2006.01)

CPC A61K 31/4174 (2013.01) [A61K 9/06 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/5015 (2013.01); A61K 31/343 (2013.01); A61K 31/4196 (2013.01); A61K 31/496 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61P 31/10 (2018.01); B01J 13/08 (2013.01)]

24 Claims

1. Encapsulated particles comprising one or more particle cores of hydrolysable silicon-containing material, the one or more particle cores comprising at least 50% by weight elemental silicon; and an active pharmaceutical ingredient (API) present at between 0.1% and 20% by weight of the total encapsulated particle weight, wherein the API is an anti-fungal agent; wherein the one or more particle cores are encapsulated in a waxy lipid shell comprising:

a) two lipidic components present at from 55% to 95% of the total encapsulated particle weight;

b) a surfactant present at from 0.1% to 5% by weight of the total encapsulated particle weight;

c) a co-surfactant present at from 0.01% to 1% by weight of the total encapsulated particle weight; and

d) a regulator of metastable state present at from 0.1% to 5% by weight of the total encapsulated particle weight, wherein the regulator of metastable state is selected from one or more of: terpenes; terpenoids; C₁₄to C₂₂fatty acids, pegylated by methyl ether of polyethylene glycol (PEG); diacylphosphatidylethanolamines pegylated with PEG; poloxamers; and derivatives thereof.